These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25953139)

  • 21. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
    Rodríguez-Torres M
    Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).
    Sheridan DA; Neely RD; Bassendine MF
    Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):10-6. PubMed ID: 22959093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lawsuit seeks access to data from hepatitis C drug trial.
    McCarthy M
    BMJ; 2015 Jun; 350():h3564. PubMed ID: 26126508
    [No Abstract]   [Full Text] [Related]  

  • 26. Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects.
    Liu J; Jadhav PR; Amur S; Fleischer R; Hammerstrom T; Lewis L; Naeger L; O'Rear J; Pacanowski M; Robertson S; Seo S; Soon G; Birnkrant D
    Hepatology; 2013 Mar; 57(3):897-902. PubMed ID: 22487907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.
    Florian J; Jadhav PR; Amur S; Ayala R; Harrington P; Mishra P; O'Rear J; Pacanowski M; Robertson S; Singer M; Soon G; Zeng W; Murray J
    Hepatology; 2013 Mar; 57(3):903-7. PubMed ID: 22610696
    [No Abstract]   [Full Text] [Related]  

  • 30. TMC435 for the treatment of chronic hepatitis C.
    Tanwar S; Trembling PM; Dusheiko GM
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1193-209. PubMed ID: 22616626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs.
    Kraus VB; Simon LS; Katz JN; Neogi T; Hunter D; Guermazi A; Karsdal MA
    Osteoarthritis Cartilage; 2019 Apr; 27(4):571-579. PubMed ID: 30465809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
    Mishra P; Florian J; Peter J; Vainorius M; Fried MW; Nelson DR; Birnkrant D
    Gastroenterology; 2017 Sep; 153(3):626-631. PubMed ID: 28757271
    [No Abstract]   [Full Text] [Related]  

  • 33. US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals.
    Hey SP; Kesselheim AS; Patel P; Mehrotra P; Powers JH
    JAMA Intern Med; 2020 Jan; 180(1):131-138. PubMed ID: 31710344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection.
    Dick TB; Lindberg LS; Ramirez DD; Charlton MR
    Hepatology; 2016 Feb; 63(2):634-43. PubMed ID: 26033675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA: evidentiary standards for drug development and approval.
    Katz R
    NeuroRx; 2004 Jul; 1(3):307-16. PubMed ID: 15717032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
    Sasinowski FJ; Varond AJ
    Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA bridging analyses confirmed in clinical trial.
    Mishra P; Florian J; Murray J
    Hepatology; 2014 Dec; 60(6):2134. PubMed ID: 24591059
    [No Abstract]   [Full Text] [Related]  

  • 39. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
    Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.